Key result
Higher plasma RIPK3 is associated with increased MACE risk after PCI for acute MI.
Why the study?
Is there a positive relationship between plasma RIPK3 concentrations and the risk of major adverse cardiovascular events in patients with acute myocardial infarction receiving PCI?
Observational
Is there a positive relationship between plasma RIPK3 concentrations and the risk of major adverse cardiovascular events in patients with acute myocardial infarction receiving PCI?
Extracellular RIPK3 is associated with increased risk of MACE in AMI patients post-PCI and acts as a damage-associated molecular pattern mediating cardiac ischemia/reperfusion injury, highlighting it as a potential therapeutic target.
We identified the positive relationship between plasma RIPK3 concentrations and the risk of major adverse cardiovascular events in patients with acute myocardial infarction receiving PCI. As a damage-associated molecular pattern, extracellular RIPK3 plays a causal role in multiple pathological conditions during cardiac I/R injury through RAGE/CaMKII signaling. These findings expand our understanding of the physiological and pathological roles of RIPK3, and also provide a promising therapeutic target for myocardial I/R injury and the associated complications.
No takes yet. Share an insight, caveat, or question.
Zhang et al. (2024) conducted an observational in Acute myocardial infarction. Plasma RIPK3 concentrations was evaluated on Major adverse cardiovascular events. Plasma RIPK3 concentrations were positively associated with the risk of major adverse cardiovascular events in patients with acute myocardial infarction receiving PCI.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: